North Star Asset Management Inc. lowered its position in Hologic Inc. (NASDAQ:HOLX) by 0.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 167,551 shares of the company’s stock after selling 360 shares during the period. North Star Asset Management Inc.’s holdings in Hologic were worth $5,797,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in HOLX. State Street Corp raised its stake in shares of Hologic by 26.4% in the first quarter. State Street Corp now owns 10,295,836 shares of the company’s stock worth $355,210,000 after buying an additional 2,150,544 shares during the period. Wedge Capital Management L L P NC bought a new stake in shares of Hologic during the second quarter worth about $48,888,000. Old Mutual Global Investors UK Ltd. raised its stake in shares of Hologic by 276.7% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 1,818,296 shares of the company’s stock worth $62,913,000 after buying an additional 1,335,551 shares during the period. Panagora Asset Management Inc. raised its stake in shares of Hologic by 247.3% in the first quarter. Panagora Asset Management Inc. now owns 1,682,853 shares of the company’s stock worth $58,058,000 after buying an additional 1,198,338 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Hologic by 54.3% in the first quarter. Geode Capital Management LLC now owns 2,328,326 shares of the company’s stock worth $80,187,000 after buying an additional 819,646 shares during the period. 94.51% of the stock is currently owned by institutional investors.
Hologic Inc. (NASDAQ:HOLX) traded up 0.326% during trading on Friday, hitting $38.445. The company had a trading volume of 595,177 shares. The stock has a 50-day moving average of $38.49 and a 200-day moving average of $36.33. The stock has a market capitalization of $10.67 billion, a PE ratio of 42.387 and a beta of 1.00. Hologic Inc. has a one year low of $31.84 and a one year high of $41.66.
Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, July 27th. The company reported $0.51 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.48 by $0.03. Hologic had a return on equity of 26.25% and a net margin of 9.39%. The firm had revenue of $717.40 million for the quarter, compared to the consensus estimate of $703.66 million. During the same quarter last year, the business posted $0.43 EPS. The company’s revenue for the quarter was up 3.4% on a year-over-year basis. On average, equities analysts anticipate that Hologic Inc. will post $1.94 EPS for the current year.
A number of equities research analysts have recently issued reports on HOLX shares. Piper Jaffray Cos. set a $40.00 target price on Hologic and gave the stock a “hold” rating in a research report on Monday, July 25th. They noted that the move was a valuation call. Barclays PLC upgraded Hologic from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $42.00 to $44.00 in a report on Friday, September 23rd. Evercore ISI upgraded Hologic from a “hold” rating to a “buy” rating and lifted their price target for the company from $38.00 to $42.00 in a report on Thursday, July 28th. Canaccord Genuity set a $45.00 price target on Hologic and gave the company a “buy” rating in a report on Thursday, July 28th. Finally, Jefferies Group lifted their price target on Hologic from $42.00 to $43.00 and gave the company a “buy” rating in a report on Thursday, July 28th. Six investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $42.71.
In other news, Director Elaine Ullian sold 18,236 shares of the firm’s stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $39.88, for a total value of $727,251.68. Following the completion of the transaction, the director now owns 42,898 shares in the company, valued at approximately $1,710,772.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Nancy Leaming sold 8,179 shares of the firm’s stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $37.00, for a total value of $302,623.00. Following the completion of the transaction, the director now owns 67,140 shares of the company’s stock, valued at approximately $2,484,180. The disclosure for this sale can be found here. 0.84% of the stock is owned by company insiders.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.